Evaluation of Calretinin and enumeration of mast cells in rectum tissue biopsies of Hirschsprung and non-Hirschsprung disease in neonate and infant-Reference-Cited by-同舟云学术

Evaluation of Calretinin and enumeration of mast cells in rectum tissue biopsies of Hirschsprung and non-Hirschsprung disease in neonate and infant

Published:2023-12-15 Issue:4 Volume:8 Page:1-16
ISSN:1390-9347
Container-title:Bionatura
language:
Short-container-title:RB

Author:

Abdul Hussein Rusul A.¹,AL-Sharqi Sahar A. H.¹,Mehdi Nada K.²,Joda Ali E.³

Affiliation:

1. Department of Biology, College of Science, Mustansiriyah University, Baghdad/Iraq

2. Histopathology Specialist, Central Child Teaching Hospital, Baghdad, Iraq

3. Pediatrics department, College of Medicine, Mustansiriyah University, Baghdad/Iraq 5 Consultant pediatric surgeon, Central Child Teaching Hospital, Baghdad, Iraq

Abstract

The Hirschsprung disease (HD) is a complex genetic congenital condition characterized by the absence of ganglion cells in the myenteric and submucosal plexuses of the colon and rectum, leading to functional intestinal obstruction. A study was conducted from July 2022 to December 2022. The Toluidine blue stain and calretinin immunohistochemistry were applied to 36 cases of neonates and infants who clinically presented with symptoms suspicious of having HD, And the hematological study of cell blood counts test and compared the result of the HD group with the non-HD group and control group. The study showed an increase in mast cell numbers in the rectal biopsy tissue of HD patients compared with non-HD patients using Toluidine blue stain. The Immunohistochemistry for calretinin result displayed 27 (75%) cases as HD, while the remaining 9 (25%) cases were confirmed as non-HD and showed hypertrophied nerve fiber in HD cases. at the same time, the complete blood count result was unrelated to HD. Some worrying maternal risk factors were highlighted during pregnancy were the age of the mother at conception, maternal illness, intake of drugs, type of Childbirth, and number of previous maternal abortions; all of them show a non-significant difference between the HD group and non-HD group, also consanguineous marriage was detected and shows a significant difference between the HD group and non-HD group. Keywords: Hirschsprung, Calretinin, Toluidine blue, CBC count

Publisher

Clinical Biotec

Subject

Infectious Diseases,Applied Microbiology and Biotechnology,Epidemiology,Biotechnology

Reference78 articles.

1. 1. Klein M, Varga I. Hirschsprung's disease-recent understanding of embryonic aspects, etiopathogenesis and future treatment avenues. Medicina (Kaunas) Internet. 2020; 56(11):611. Available from: http://dx.doi.org/10.3390/medicina56110611.

2. 2. Gustafson E, Larsson T, Danielson J. Controlled outcome of Hirschsprung's disease beyond adolescence: a single center experience. Pediatr Surg Int Internet. 2019;35(2):181–5. Available from: http://dx.doi.org/10.1007/s00383-018-4391-5.

3. 3. Holschneider AM, Meier-Ruge W, Ure BM. Hirschsprung's disease and allied disorders--a review. Eur J Pediatr Surg Internet. 1994;4(5):260–6. Available from: http://dx.doi.org/10.1055/s-2008-1066115.

4. 4. Gorbatyuk OM. Current approaches to diagnosis and treatment of Hirschsprung disease in newborns and infants (literature review and first-hand experience). Wiad Lek Internet. 2022;75(4):1026–30. Available from: http://dx.doi.org/10.36740/wlek20220420120.

5. 5. Bahrami A, Joodi M, Moetamani-Ahmadi M, Maftouh M, Hassanian SM, Ferns GA, et al. Genetic background of hirschsprung disease: A bridge between basic science and clinical application. J Cell Biochem Internet. 2018;119(1):28–33. Available from: http://dx.doi.org/10.1002/jcb.26149.